Submited on: 22 Dec 2011 10:56:35 PM GMT
Published on: 23 Dec 2011 06:19:14 PM GMT
Emergence of Vancomycin-Resistant Staphylococcus Aureus (VRSA)
Posted by Ms. Chanah Gallagher on 01 Nov 2017 03:01:59 PM GMT Reviewed by Interested Peers

  • What are the main claims of the paper and how important are they?

    The main claim of this paper is that VRSA is an emerging problem caused by the increased use of vancomycin to treat the ever-eminent MRSA infection allowing for inducible resistance to vancomycin. They further discuss that the main treatment options currently are combination therapies such as Synercid.  

  • Are these claims novel? If not, please specify papers that weaken the claims to the originality of this one.

    No. However, unlike the provided examples the paper does go into more detail about treatment options. (These are only a couple of examples, there are other articles that review VRSA)

    The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus

    VISA, hetero-VISA and VRSA: The end of the vancomycin era?

  • Are the claims properly placed in the context of the previous literature?


  • Do the results support the claims? If not, what other evidence is required?


  • If a protocol is provided, for example for a randomized controlled trial, are there any important deviations from it? If so, have the authors explained adequately why the deviations occurred?

    Not applicable

  • Is the methodology valid? Does the paper offer enough details of its methodology that its experiments or its analyses could be reproduced?

    Not applicable

  • Would any other experiments or additional information improve the paper? How much better would the paper be if this extra work was done, and how difficult would such work be to do, or to provide?

    It could be helpful to include more detail in the “Treatment for Staphylococcus aureus” section in order to better introduce and correlate with the following section “Why Difficult to Treat Infection Caused by Staphylococcus aureus”. It could also be helpful in the “Treatment for VISA, VRSA and Hetero-VRSA” section to provide more details about Synercid and antimicrobial stewardship as treatment options. These additions would not be difficult and they would improve the article, but they are not needed for the article to hold merit.

  • Is this paper outstanding in its discipline? (For example, would you like to see this work presented in a seminar at your hospital or university? Do you feel these results need to be incorporated in your next general lecture on the subject?) If yes, what makes it outstanding? If not, why not?

    This is a well-written paper with a few grammatical errors. This paper should be included in my next lecture discussing the subject area because it does well to address an issue that needs awareness and combative action.

  • Other Comments:


  • Competing interests:
  • Invited by the author to review this article? :
  • Have you previously published on this or a similar topic?:
  • References:


  • Experience and credentials in the specific area of science:

    Doctorate of Pharmacy and Master of Pharmaceutical Sciences Student

  • How to cite:  Gallagher C .Emergence of Vancomycin-Resistant Staphylococcus Aureus (VRSA)[Review of the article 'Emergence of Vancomycin-Resistant Staphylococcus Aureus (VRSA) ' by Murugaiyah V].WebmedCentral 2017;8(11):WMCRW003377
1 2 3 4 5 6 7 8 9
Report abuse